Key result
Sevoflurane exposure linked to ~84% higher incident dementia risk vs propofol.
Why the study?
Whether perioperative EHR records of sevoflurane and propofol identify clinically meaningful differences in long-term dementia risk is uncertain.
Does sevoflurane increase the risk of incident coded dementia compared to propofol in older adults undergoing major inpatient surgery?
Cohort (n=70,726)
Yes
Does sevoflurane increase the risk of incident coded dementia compared to propofol in older adults undergoing major inpatient surgery?
In older surgical adults, same-day EHR-coded sevoflurane exposure was associated with a higher incidence of subsequent coded dementia compared to propofol, though causal inference is limited by observational design and exposure misclassification.
Answers are grounded in this paper and cite their sources.
Sevoflurane-coded exposure signals higher dementia incidence in matched older adults; leaves open causality amid confounding and precludes practice change.
Whether perioperative EHR records of sevoflurane and propofol identify clinically meaningful differences in long-term dementia risk is uncertain. We compared same-day EHR-coded sevoflurane versus propofol exposure in relation to subsequent coded dementia among older adults undergoing major inpatient surgery. We conducted a multinational propensity-score-matched cohort study using the TriNetX federated EHR network. Adults aged 60 years or older undergoing major inpatient surgery from January 1, 2010, to December 31, 2024, were classified by a same-calendar-day record of the index procedure and sevoflurane or propofol. The aggregate export did not consistently provide route, bolus-versus-infusion status, dose, duration, or anesthesia timestamps; therefore, exposure groups were interpreted as EHR-coded patterns rather than validated exclusive maintenance regimens. The primary outcome was incident coded dementia from index + 1 day. Death was treated as censoring for the cause-specific Cox estimand. Sensitivity analyses included 90- and 180-day landmarks, a higher-specificity dementia definition, stricter exposure coding, and a 5-year dementia-or-death composite. After matching, 35,363 patients were included in each group. Matching retained 99.94% of the sevoflurane-coded cohort but 2.49% of the much larger propofol-coded cohort. Coded dementia occurred in 701 patients (1.98%) in the sevoflurane-coded group and 384 (1.09%) in the propofol-coded group (hazard ratio [HR], 1.84; 95% CI, 1.62–2.08; P < 0.001). The 5-year dementia-or-death composite occurred in 3,024 patients (8.55%) and 2,195 patients (6.21%), respectively (HR, 1.43; 95% CI, 1.33–1.52). Most measured covariates were balanced after matching, although residual imbalance remained for diastolic blood pressure and C-reactive protein. In a selected matched common-support EHR population, same-day sevoflurane-coded exposure was associated with a higher subsequent incidence of coded dementia than same-day propofol-coded exposure. Exposure misclassification, restricted overlap, residual confounding, surveillance differences, and competing mortality preclude causal inference or prescribing recommendations.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) conducted a cohort in Major inpatient surgery (n=70,726). Sevoflurane vs. Propofol was evaluated on incident coded dementia from index + 1 day (HR 1.84, 95% CI 1.62-2.08, p=<0.001). Same-day EHR-coded sevoflurane exposure was associated with a higher incidence of coded dementia compared to propofol exposure.
Synapse has enriched 10 related papers. Consider them for comparative context: